Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FINOX Biotech has submitted the Marketing Authorisation Application (MAA) for its biosimilar recombinant Follicle Stimulating Hormone (r-FSH) BEMFOLA to the European Medicines Agency.
Subscribe to our email newsletter
The submission was based on a comprehensive clinical development program, in which BEMFOLA had shown to be statistically equivalent to the reference product in patients participating in an Assisted Reproductive Technology (ART) pivotal phase 3 clinical trial.
FINOX Biotech chief executive officer Anjan Selz said the recent eCTD submission represents five years of concentrated development efforts.
”We now focus on working together with the Health Authorities in order to give the European ART patients access to this valuable medicine as soon as possible," Selz added.